

CONCLUSION

Almost all of the world's key antimicrobials have been developed in the past 80 years, roughly one human lifetime, yet their current misuse is a key factor in the emergence of resistance and their potential loss of efficacy. There has never been a more important time to understand the key features of these compounds, how to use (or not use) them effectively, and how to preserve their value for future generations.

REFERENCES

- Antibiotic Expert Group (2014). *Therapeutic Guidelines: Antibiotic*. 15th ed. Melbourne: Therapeutic Guidelines Limited, 2014.
- Australian Government, Department of Health, Department of Agriculture (2015). Responding to the Threat of antimicrobial resistance. health.gov.au/internet/main/publishing.nsf/.../amr-strategy-2015-2019.pdf. Accessed 15 July 2016.
- Barlam TF, Cosgrove SE, Abbo LM, et al. (2016). Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis* **62**: e51.
- Barreiro P, Fernández-Montero JV, de Mendoza C, Labarga P, Soriano V (2014). Pharmacogenetics of antiretroviral therapy. *Expert Opin Drug Metab Toxicol* **10**: 1119.
- Boucher HW, Talbot GH, Benjamin DK Jr, et al. (2013). 10 × '20 Progress—development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. *Clin Infect Dis* **56**: 1685.
- Brennan A, Browne JP, Horgan M (2014). A systematic review of health service interventions to improve linkage with or retention in HIV care. *AIDS Care* **26**: 804.
- Carpenter CC, Cooper DA, Fischl MA, et al. (2000). Antiretroviral therapy in adults: updated recommendations of the International AIDS Society—USA Panel. *JAMA* **283**: 381.
- Cosgrove SE, Hermsen ED, Rybak MJ, et al. (2014). Guidance for the knowledge and skills required for antimicrobial stewardship leaders. *Infect Control Hosp Epidemiol* **35**: 1444.
- Davies S (2013). Annual report of the Chief Medical Officer, 2011—volume 2. gov.uk/government/publications/chief-medical-officer-annual-report-volume-2. Accessed 16 July 2016.
- de Kanter CT, Drenth JP, Arends JE, et al. (2014). Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. *Clin Pharmacokinet* **53**: 409.
- File TM Jr, Solomkin JS, Cosgrove SE (2011). Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs. *Clin Infect Dis* **53** (Suppl 1): S15.
- Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. (2016). Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. *JAMA* **315**: 1864.
- Gelband H, Miller-Petrie M, Pant S, et al. (2015) The state of the world's antibiotics. cddep.org/sites/default/files/swa_2015_final.pdf. Accessed 15 July 2016.
- Gerber JS, Prasad PA, Fiks AG, et al. (2014). Durability of benefits of an outpatient antimicrobial stewardship intervention after discontinuation of audit and feedback. *JAMA* **312**: 2569.
- Grayson ML, Jarvie LJ, Martin R, et al. (2008). Significant reductions in methicillin-resistant *Staphylococcus aureus* bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. *Med J Aust* **188**: 633.
- Grayson ML, Russo PL, Cruickshank M, et al. (2011). Outcomes from the first 2 years of the Australian National Hand Hygiene Initiative. *Med J Aust* **195**: 615.
- Günthard HF, Saag MS, Benson CA, et al. (2016). Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society—USA Panel. *JAMA* **316**: 191.
- Laxminarayan R (2014). Antibiotic effectiveness: balancing conservation against innovation. *Science* **345**: 1299.
- Laxminarayan R, Amabile-Cuevas CF, Cars O et al. (2016a). UN high-level meeting on antimicrobials—what do we need? *Lancet* **388**: 218.
- Laxminarayan R, Duse A, Wattal C, et al. (2013). Antibiotic resistance—the need for global solutions. *Lancet Infect Dis* **13**: 1057.
- Laxminarayan R, Matsoso P, Pant S, et al. (2016b). Access to effective antimicrobials: a worldwide challenge. *Lancet* **387**: 168.
- Mitchell BG, Collignon PJ, McCann R, et al. (2014). A major reduction in hospital-onset *Staphylococcus aureus* bacteremia in Australia—12 years of progress: an observational study. *Clin Infect Dis* **59**: 969.
- Mouton JW, Ambrose PG, Canton R, et al. (2011). Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. *Drug Resist Updat* **14**: 107.
- Muller AE, Theuretzbacher U, Mouton JW (2015). Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. *Clin Microbiol Infect* **21**: 881.
- Nathanson E, Nunn P, Uplekar M, et al. (2010). MDR tuberculosis—critical steps for prevention and control. *N Engl J Med* **363**: 1050.
- Nussenblatt V, Avdic E, Cosgrove S (2013). What is the role of antimicrobial stewardship in improving outcomes of patients with CAP? *Infect Dis Clin North Am* **27**: 211.
- O'Neill J (2016). *Tackling Drug-Resistant Infections Globally: Final Report and Recommendations*. London: HM Government/Wellcome Trust.
- Pau AK, George JM (2014). Antiretroviral therapy: current drugs. *Infect Dis Clin North Am* **28**: 371.
- Pittet D, Hugonnet S, Harbarth S, et al. (2000). Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. *Lancet* **356**: 1307.
- Pulcini C, Bush K, Craig WA, et al. (2012). Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. *Clin Infect Dis* **54**: 268.
- Raffe S, Fisher M (2015). The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir + cobicistat + emtricitabine + tenofovir combination therapy for the treatment of HIV. *Expert Opin Drug Metab Toxicol* **11**: 427.
- Schaefer KL (2013). The importance of treatment adherence in HIV. *Am J Manag Care* **19** (Suppl 12): s231.
- Schuts EC, Hulscher ME, Mouton JW, et al. (2016). Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *Lancet Infect Dis* **16**: 847.
- Smolders EJ, de Kanter CT, van Hoek B, et al. (2016). Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. *Drug Saf* **39**: 589.
- Spellberg B, Srinivasan A, Chambers HF (2016). New societal approaches to empowering antibiotic stewardship. *JAMA* **315**: 1229.
- Stockmann C, Roberts JK, Knackstedt ED, et al. (2015). Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. *Expert Opin Drug Metab Toxicol* **11**: 205.
- White House (2015). National action plan for combating antibiotic resistant bacteria. whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibiotic-resistant_bacteria.pdf. Accessed 15 July 2016.
- Van Boeckel TP, Brower C, Gilbert M, et al. (2015). Global trends in antimicrobial use in food animals. *Proc Natl Acad Sci U S A* **112**: 5649.
- Van Boeckel TP, Gandra S, Ashok A, et al. (2014). Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. *Lancet Infect Dis* **14**: 742.
- WHO (World Health Organization) (2012). The evolving threat of antimicrobial resistance—Options for action. who.int/patientsafety/implementation/amr/publication/en. Accessed 15 July 2016.
- WHO (World Health Organization) (2015). *Global Action Plan on Antimicrobial Resistance*. Geneva: World Health Organization. who.int/drugresistance/global_action_plan/en. Accessed 16 July 2016.
- WHO (World Health Organization) (2001). WHO global strategy for containment of antimicrobial resistance. who.int/drugresistance/WHO_Global_Strategy_English.pdf. Accessed 15 July 2016.